SCHEMBL24256434

SCHEMBL24256434

CC(=O)N(CCC(C)C)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
CA1 P00915 3/20 0.36
TDP1 Q9NUW8 1/20 0.35
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
PIK3CD O00329 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
POLB P06746 1/20 0.32
THRB P10828 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KDM4C Q9H3R0 2/20 0.32
KDM4A O75164 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7930800 0.85 CHRM1 (0.35) ALDH1A1TDP1CHRM2CHRM4CHRM5
SCHEMBL25867886 0.85 KDM4C (0.40) CA1LMNAKDM4CKDM4APHF8
SCHEMBL21729304 0.84 ALDH1A1 (0.35) ALDH1A1CA1CA12CA2CA9
SCHEMBL5207724 0.80 CA1 (0.41) ALDH1A1CA1TDP1CA12CA2
SCHEMBL14276891 0.78 MAPT (0.39) ALDH1A1TDP1CHRM2CHRM4CHRM5
SCHEMBL12384299 0.78 ALDH1A1 (0.38) ALDH1A1CA1TDP1CA12CA2
SCHEMBL15223832 0.78 CHRM1 (0.36) ALDH1A1TDP1CA12CA2CA9
SCHEMBL497808 0.78 CA12 (0.36) ALDH1A1CA1TDP1CA12CA2
SCHEMBL18913393 0.77 ALDH1A1 (0.34) ALDH1A1CA1CA12CA2CA9
SCHEMBL17663683 0.77 ALDH1A1 (0.39) ALDH1A1CA1TDP1CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed
WO-2022035997-A1 IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS AVILAR THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A ALDH1A1 3319/4885CA1 4078/4885TDP1 3930/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A ALDH1A1 3256/4885CA1 3524/4885TDP1 4559/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R ALDH1A1 4019/4885CA1 4533/4885TDP1 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.